Supreme Court Lets Vioxx Securities Suit Against Merck Stand
This article was originally published in The Pink Sheet Daily
Executive Summary
The top U.S. court clarifies when the statute of limitations for filing suit begins to run and specifies that intent to deceive is crucial in determining if a violation occurred.
You may also be interested in...
Judge Gorsuch Could Be Pharma Ally In FDA Disputes
Supreme Court nominee's opposition to deference for administrative agencies could help biopharma industry in its battle over off-label communications if the issue ever goes before the court; he also supports securities litigation reform.
Pharma Securities Fraud Worries Reduced In Supreme Court Omnicare Ruling
High court finds that a corporation’s statement of opinion is not actionable unless company did not sincerely believe it; ruling makes it harder for plaintiffs to file stock fraud claims.
Pharma Securities Fraud Worries Reduced In Supreme Court Omnicare Ruling
High court finds that a corporation’s statement of opinion is not actionable unless company did not sincerely believe it; ruling makes it harder for plaintiffs to file stock fraud claims.